



Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Group Art Unit: 1652

Filed: June 24, 1999

Examiner: Prouty, R.

For: Novel Mannanases

RECEIVED
MAY 26 2000
TECH CENTER 1600/2900

SUBMISSION OF SEQUENCE LISTING

Box Sequence
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Sequence Rules dated May 10, 2000, please amend the above-captioned application as follows:

IN THE SPECIFICATION:

Please delete pages 1-35 and insert the attached Sequence Listing (pages 1-32).

REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing.

The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein.


This submission contains no new matter.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 22, 2000



Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123